Docket commenters call for flexibility in rare disease trial design and evidence, but question FDA’s RCT focus
Comments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare disease clinical investigations supported the need for flexibility in trial design and evidence for rare diseases, but a few asked the agency to reconsider its focus on randomized controlled trials.
20 Nov 2026 This Week at FDA: Overton nomination pulled, FDA promotes international reliance, and more Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, the Trump administration withdrew its FDA commissioner nominee at the eleventh hour, FDA announced a program to help sponsors market products in other countries, and announced several firsts in product approvals. This Week at FDA
comments(0)
5-min edit window · permanent after that